Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.

A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin

Open access

Published version of a preprint

Abstract

Purpose: Defects in the homologous recombination (HR) repair pathway are of clinical interest due to sensitivity of HR-deficient cells to PARP inhibitors. We were interested in defining PARP vulnerability in patients with metastatic colorectal cancer (mCRC) carrying KRAS and BRAF mutations who display poor prognosis, have limited therapeutic options, and represent an unmet clinical need. Experimental Design: We tested colorectal cancer cell lines, patient-derived organoids (PDO), and patient-derived xenografts (PDX) enriched for KRAS and BRAF mutations for sensitivity to the PARP inhibitor olaparib, and the chemotherapeutic agents oxaliplatin and 5-fluorouracil (5-FU). Genomic profiles and DNA repair proficiency of colorectal cancer models were compared with pharmacologic response. Results: Thirteen of 99 (around 13%) colorectal cancer cell lines were highly sensitive to clinically active concentrations of olaparib and displayed functional deficiency in HR. Response to PARP blockade was positively correlated with sensitivity to oxaliplatin in colorectal cancer cell lines as well as patient-derived organoids. Treatment of PDXs with olaparib impaired tumor growth and maintenance therapy with PARP blockade after initial oxaliplatin response delayed disease progression in mice. Conclusions: These results indicate that a colorectal cancer subset characterized by poor prognosis and limited therapeutic options is vulnerable to PARP inhibition and suggest that PDO-based drug-screening assays can be used to identify patients with colorectal cancer likely to benefit from olaparib. As patients with mCRC almost invariably receive therapies based on oxaliplatin, “maintenance” treatment with PARP inhibitors warrants further clinical investigation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-19-2409

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 63 references

Cited by

See all 117

Metadata

Authors
Arena, S., Corti, G., Durinikova, E., Montone, M., Reilly, N. M., Russo, M., Lorenzato, A., Arcella, P., Lazzari, L., Rospo, G., Pagani, M., Cancelliere, C., Negrino, C., Isella, C., Bartolini, A., Cassingena, A., Amatu, A., Mauri, G., Sartore-Bianchi, A., Mittica, G., Medico, E., Marsoni, S., Linnebacher, M., Abrignani, S., Siena, S., Di Nicolantonio, F., & Bardelli, A.
Affiliations
  • Candiolo Cancer Institute (IT)
  • Fondazione Piemontese per la Ricerca sul Cancro Onlus (IT)
  • IFOM (IT)
  • University of Milan (IT)
  • Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
  • 7Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.
  • 1Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy.
  • University of Rostock (DE)
Corresponding author
Bardelli, Alberto
Venue
Clinical Cancer Research
Published
2020-03-13
Volume
26
Issue
6
Pages
1372-1384
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2996516440
Cited by
115
References
63
Citations by year
2026: 6 · 2025: 14 · 2024: 12 · 2023: 16 · 2022: 22 · 2021: 38 · 2020: 7
FWCI
7.06
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
Funders
  • AIRC (2018-ID. 21091, 2017-ID 20236, IG 2018-ID. 21923, IG no. 17707, IG no. 21407, 20685)
  • European Community's Seventh Framework Programme (602901)
  • H2020 (635342-2)
  • IMI (115749)
  • Ministero della Salute (NET 02352137)
  • JTC (TRS-2015-00000060)
Topics
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords
metastatic colorectal cancer, olaparib, PARP inhibitors, oxaliplatin, homologous recombination deficiency, KRAS mutation, BRAF mutation, 5-fluorouracil, patient-derived organoids, patient-derived xenografts, drug sensitivity, maintenance therapy, DNA repair
MeSH terms
Poly(ADP-ribose) Polymerase Inhibitors, Oxaliplatin, Animals, Antineoplastic Agents, Humans, Mutation, Phthalazines, Piperazines, Colorectal Neoplasms, Gene Expression Regulation, Neoplastic, Proto-Oncogene Proteins p21(ras), Mice, SCID, Mice, Inbred NOD, Treatment Outcome, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Cell Line, Tumor, Proto-Oncogene Proteins B-raf, Mice, Recombinational DNA Repair

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-2409
The paper
Arena, S., Corti, G., Durinikova, E., Montone, M., Reilly, N. M., Russo, M., Lorenzato, A., Arcella, P., Lazzari, L., Rospo, G., Pagani, M., Cancelliere, C., Negrino, C., Isella, C., Bartolini, A., Cassingena, A., Amatu, A., Mauri, G., Sartore-Bianchi, A., . . . Bardelli, A. (2020). A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-2409

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.